

Date: 14.02.2022

To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001.

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 14.02.2022

Ref: Regulation 30 and 33 along with Schedule III of SEBI(LODR) Regulations, 2015

With reference to the subject cited, this is to inform the exchanges that at the Board Meeting of Sangam Healthcare Products Limited held on Monday, 14.02.2022 at 04.00 P.M at the registered office of the company, approved the following items of business:

1. Unaudited financial results for the quarter ended 31.12.2021 (enclosed).
2. Limited Review Report for the quarter ended 31.12.2021.(enclosed)

The meeting concluded at 5:45 P.M.

This is for your information and records.

Thanking You,

For and on Behalf of the
Sangam Healthcare Products Limited



A. Balagopal
Chairman
DIN:01712903

SANGAM HEALTHCARE PRODUCTS LIMITED							
Statement of Un-Audited Results for the Quarter Ended and Nine Months Ended 31.12.2021 (Rs. in Lakhs)							
S.No.	Particulars	For the Quarter ended			Nine Months Ended		Year Ended
		31.12.2021 (unaudited)	30.09.2021 (unaudited)	31.12.2020 (unaudited)	31.12.2021 (unaudited)	31.12.2020 (unaudited)	31.03.2021 (audited)
I.	Revenue from Operations	370.58	88.41	223.92	504.67	848.30	953.71
II.	Other Income	6.90	-	-	6.90	-	1.78
III.	Total income (I+II)	377.48	88.41	223.92	511.57	848.30	955.49
IV.	Expenses						
	(a) Cost of Materials consumed	309.04	87.76	84.49	415.72	317.72	391.19
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-30.22	-26.43	-4.32	-40.15	155.35	174.05
	(d) Employee benefits expense	97.22	0.66	329.83	116.38	436.81	291.61
	(e) Finance Cost	10.33	0.29	0.53	10.89	0.65	7.42
	(f) Depreciation and amortisation expense	27.36	27.56	31.39	82.68	94.16	121.72
	(g) Capital Expenditure Written Off	-	-	-	-	-	-
	(h) Net loss on de-recognition of financial assets at amortized cost	-	-	-	-	-	-
	(i) Net loss on reclassification of financial assets	-	-	-	-	-	-
	(j) Other expenses	87.85	31.21	65.68	137.29	199.25	228.56
	Total Expenses	501.78	121.05	507.61	722.81	1,203.95	1,214.55
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	-124.29	-32.64	-281.69	-211.23	-355.65	(259.06)
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit / (Loss) from before tax (V-VI)	-124.29	-32.64	-281.69	-211.23	-355.65	(259.06)
VIII.	Tax expense						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	(29.19)
IX.	Net Profit / (Loss) for the year from continuing operations (VII-VIII)	-124.29	-32.64	-281.69	-211.23	-355.65	(229.87)
	Discontinued Operations						
X.	Profit/(Loss) from discontinued operations	-	-	-	-	-	-
XI.	Tax expenses of discontinued operations	-	-	-	-	-	-
XII.	Net Profit / (Loss) for the year from Discontinuing operations (X-XI)	-	-	-	-	-	-
XIII.	Profit/(Loss) for the year (IX+XII)	-124.29	-32.64	-281.69	-211.23	-355.65	(229.87)
XIV.	Other Comprehensive Income(OCI)						
	Items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XV.	Total Comprehensive Income	-124.29	-32.64	-281.69	-211.23	-355.65	(229.87)
XVI.	Fair-up equity share capital (Face Value of Rs. 10/- per share)	1,486.07	1,486.07	1,486.07	1,486.07	1,486.07	1,486.07
XVII.	Earnings Per Equity Share of face value of Rs.10/- each						
	a) Basic & Diluted (In Rs.)	(0.84)	(0.22)	(1.90)	(1.42)	(2.39)	(1.55)

NOTES:

- The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 14/02/2022.
- These results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued there under and other accounting pronouncements generally accepted in India.
- The Company is engaged in manufacturing and sale of medical products hence there are no separate reportable segments as per Ind AS -108 "Operating Segments" is prepared.

For SANGAM HEALTHCARE PRODUCTS LIMITED

 Chairman
 Sangam Healthcare Products Ltd.
 Hyderabad
 50002903

Place : Hyderabad
 Date : 14/02/2022

SANGAM HEALTHCARE PRODUCTS LIMITED
205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD
UNAUDITED BALANCE SHEET AS AT 31st DECEMBER 2021

(Rs. in Lakhs)

	PARTICULARS	As at Dec 31, 2021	As at March 31, 2021
I	<u>ASSETS:</u>		
(1)	Non-current assets		
	(a) Property, Plant and Equipment	419.55	502.23
	(b) Capital work-in-progress	-	-
	(c) Goodwill	-	-
	(d) Other Intangible Assets	-	-
	(e) Biological Assets	-	-
	(f) Financial assets	-	-
	(i) Investments	-	-
	(ii) Other Financial Assets	-	-
	(g) Deferred tax assets (net)	-	-
	(h) Other non-current assets	54.04	52.35
	Total	473.59	554.58
(2)	Current assets		
	(a) Inventories	116.11	105.79
	(b) Financial assets		
	(i) Investments	-	-
	(ii) Trade receivables	59.54	68.84
	(iii) Cash and cash equivalents	4.63	3.44
	(iv) Bank Balances other than (iii) above	-	-
	(v) Loans and advances	-	-
	(vi) Investments held for Sale	-	-
	(c) Current Tax Asset (Net)	0.58	0.79
	(d) Other current assets	227.08	208.48
	Total	407.95	387.34
	TOTAL ASSETS	881.53	941.92
II	<u>EQUITY AND LIABILITIES:</u>		
	Equity		
	(a) Equity Share Capital	1,486.07	1,486.07
	(b) Other Equity		
	Reserves and Surplus	-3,519.04	-3,307.80
	Total	-2,032.97	-1,821.73
	Liabilities		
(1)	Non Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	32.31	38.89
	(b) Deffered Tax Liability(Net)	39.98	39.98
	© Long Term Provisions		
	(d) Other non current liabilities	-	-




	Total	72.29	78.86
(2) Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings		2,361.80	1,782.53
(ii) Trade Payables		257.54	441.16
(iii) Other financial liabilities		-	-
(b) Other current liabilities		222.87	461.10
(c) Provisions		-	-
(d) Current tax liabilities(Net)		-	-
	Total	2,842.21	2,684.79
TOTAL EQUITY AND LIABILITIES		881.53	941.92

For SANGAM HEALTHCARE PRODUCTS LIMITED



A. Balagopal
Chairman
DIN: 01712903

Place : Hyderabad
Date : 14/02/2022

SANGAM HEALTHCARE PRODUCTS LIMITED		
205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD		
CASH FLOW STATEMENT AS ON 31.12.2021		
	Rs. In Lakhs	
PARTICULARS	12/31/2021	3/31/2021
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	-211.23	-259.06
Adjustment for:		
Depreciation and Amortisation	82.68	121.72
Finance Cost recognised in Profit or Loss	-	7.42
Investment Income recognised in Profit or Loss	-	-1.78
Cash Flows from Operations before changes in assets and liabilities	-128.55	-131.70
Movements in Working Capital::		
(Increase)/ Decrease in trade receivables	9.30	-18.74
(Increase)/Decrease in other Current Assets	-20.08	-11.19
(Increase) / Decrease in Inventories	-10.32	265.47
(Increase) / Decrease in Loans and Advances & other current Assets	-	-
Increase / (Decrease) in Trade and other payables	-183.62	-150.92
Increase / (Decrease) in Short term borrowings & provisions	-	-
Increase/(Decrease) in Other current liabilities	-238.23	60.88
Cash Generated From Operations	-571.50	13.80
Less: Taxes paid	-	-
Less: Exceptional Items	-	-
Net Cash from operating activities(A)	-571.50	13.80
B. CASH FLOW FROM INVESTING ACTIVITIES		
Proceeds from disposal of Property,Plant and Equipment	-	-
Investment in equity Shares	-	-
Interest Received	-	1.78
Net cash used in Investing activities (B)	-	1.78
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	-
Repayment of Long Term Borrowings	572.69	62.52
Interest paid	-	-7.42
Increase / (Decrease) in Provisions	-	-67.98
Net cash Flow from Financing Activities (C)	572.69	-12.89
D. Effect of exchange differences on translation of foreign currency cash and cash equivalents		
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	1.19	2.68
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	3.44	0.75
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	4.63	3.44
For SANGAM HEALTHCARE PRODUCTS LIMITED		
		
Place: Hyderabad		
Date :14/02/2022		



LIMITED REVIEW REPORT

Review report to
The Board of Directors,
SANGAM HEALTH CARE PRODUCTS LIMITED

We have reviewed the accompanying statement of Un-audited Financial Results of **SANGAM HEALTH CARE PRODUCTS LIMITED** or the quarter ended **31st December, 2021** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M M REDDY & CO.,
Chartered Accountants
Firm Reg No. 0103718

M Madhusudhana Reddy
Partner

Membership No. 213077
UDIN:22213077ACCMGU1836

Place: Hyderabad
Date: 14/02/2022

